Key themes and potential strategies for 2010................................................................................................................2
2010: Drug reimbursement list is a key differentiating factor .....................................................................................3
Valuation appears reasonable; Buy medical device and companies with incremental exposure to RDL and EDL.......5
Key changes to our numbers at a glance .......................................................................................................................9
Where will China’s pharmaceutical sector stand after five years? .................................................................11
Summary financials ..................................................................................................................................14
Disclosures ......................................................................................................................................................29